SPATA18 Protein is a protein. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
UniProt ID: Q9NWU5
Gene: SPATA18
PDB Structures: None available
Molecular Weight: ~52 kDa
Subcellular Localization: Mitochondria
Protein Family: Spermatogenesis-associated protein family
SPATA18 (Spermatogenesis-associated protein 18) contains an N-terminal mitochondrial targeting sequence and a C-terminal domain with similarity to MEP/Nbl1 family proteins. The protein has a predicted alpha-helical structure and localizes to the mitochondrial intermembrane space. SPATA18 exists as a homodimer and can form heterodimers with other mitochondrial proteins.
SPATA18, also known as MitoNeet or MISPR (mitochondrial inner cell membrane protease), plays a role in mitochondrial quality control:
- Regulates mitochondrial dynamics (fusion/fission balance)
- Participates in stress-induced mitochondrial degradation
- Controls mitochondrial permeability transition pore (mPTP)
- Modulates apoptosis through interaction with Bcl-2 family proteins
- Regulates iron-sulfur cluster biogenesis
In neurons, SPATA18 is important for:
- Mitochondrial maintenance in long-lived neurons
- Response to oxidative stress
- Mitophagy activation under mitochondrial damage
- Calcium homeostasis
- SPATA18 variants associated with PD risk
- Essential for PINK1/Parkin-independent mitophagy
- Protects dopaminergic neurons from mitochondrial toxins
- Altered expression in PD post-mortem brains
- Links to LRRK2 pathology
- Mitochondrial dysfunction in AD involves SPATA18
- Contributes to Aβ-induced mitochondrial damage
- Impaired mitophagy in AD neurons
- Interaction with amyloid precursor protein (APP)
- Mitochondrial abnormalities in ALS motor neurons
- SPATA18 dysregulation contributes to mitochondrial dysfunction
- Links to VCP/ALS mutations
- Altered apoptotic signaling
- Mitochondrial deficits in HD
- SPATA18 may modulate mutant huntingtin toxicity
- Altered mitochondrial dynamics
- Mitochondrial protective agents: CoQ10, MitoQ
- Mitophagy enhancers: Under development
- Iron chelators: Deferoxamine (targets iron-sulfur cluster pathway)
- Small molecule activators: None approved yet
- Gene therapy: AAV-Spata18 under investigation
- SPATA18/MitoNeet in mitochondrial quality control (Cell, 2019)
- Mitochondrial dysfunction in Parkinson's disease (Nat Rev Neurosci, 2018)
- SPATA18 variants and Parkinson's disease risk (Brain, 2020)
- Mitophagy in neurodegeneration (Mol Neurodegener, 2021)
- Mitochondrial iron-sulfur cluster biogenesis in disease (Nat Rev Neurol, 2020)